Leuven - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies, with a focus on diabetic macular edema (DME), announces that the Company will issue its Business Update and First Half Financial Results on Thursday, September 17, 2020 at 5.45 p.m. CET.

Following the announcement, Oxurion's management will host a conference call in English on Thursday, September 17 at 6.30 p.m. CET to discuss the Business Update, its Financial Results and to provide an overview of the progress and potential of the Company's emerging DME Franchise.

Contact:

Tel: +32 16 75 13 10

Fax: +32 16 75 13 11

(C) 2020 Electronic News Publishing, source ENP Newswire